Akari Therapeutics Plc (AKTX)
0.2366
0.00 (0.00%)
USD |
NASDAQ |
Feb 20, 16:00
0.2419
+0.01
(+2.24%)
Pre-Market: 20:00
Akari Therapeutics SG&A Expense (Quarterly) : 1.963M for Sept. 30, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| DBV Technologies SA | 8.399M |
| Cellectis SA | 5.184M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 1.886M |
| Autolus Therapeutics Plc | 36.05M |